$717 Million is the total value of BROADWOOD CAPITAL INC's 10 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
MNST | MONSTER BEVERAGE CORP NEW | $303,628,000 | +14.6% | 4,797,408 | 0.0% | 42.32% | -3.6% | |
STAA | STAAR SURGICAL CO | $168,255,000 | +24.5% | 10,855,179 | 0.0% | 23.45% | +4.8% | |
IWM | ISHARES TRrussell 2000 etf | $64,033,000 | +2.9% | 420,000 | 0.0% | 8.92% | -13.4% | |
OCX | ONCOCYTE CORPORATION | $16,725,000 | -38.4% | 3,596,680 | 0.0% | 2.33% | -48.2% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
STAAR SURGICAL CO | 45 | Q2 2024 | 59.1% |
MONSTER BEVERAGE CORP NEW | 37 | Q2 2024 | 49.7% |
ISHARES TR | 36 | Q2 2024 | 14.8% |
ONCOCYTE CORPORATION | 31 | Q2 2023 | 4.6% |
AXON ENTERPRISE INC | 27 | Q2 2024 | 17.9% |
BIOTIME INC | 25 | Q2 2019 | 17.8% |
AGEX THERAPEUTICS INC | 21 | Q4 2023 | 1.5% |
LINEAGE CELL THERAPEUTICS INC | 20 | Q2 2024 | 5.1% |
ASTERIAS BIOTHERAPEUTICS INC | 16 | Q4 2018 | 2.9% |
CYNOSURE INC | 15 | Q4 2016 | 10.4% |
View BROADWOOD CAPITAL INC's complete holdings history.
Latest filings
Type | Filed |
---|---|
N-PX | 2024-08-30 |
13F-HR | 2024-08-14 |
13F-HR | 2024-05-15 |
4 | 2024-05-13 |
4 | 2024-04-15 |
13F-HR | 2024-02-14 |
4 | 2024-02-08 |
4 | 2024-01-10 |
4 | 2024-01-05 |
4 | 2023-11-30 |
View BROADWOOD CAPITAL INC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.